Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Crucell & ADImmune Corporation.

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Crucell & ADImmune Corporation.

69 Posts
Pagina: 1 2 3 4 »» | Laatste | Omlaag ↓
  1. flosz 17 september 2008 11:58
    Even een correctie op post in draadje www.iex.nl/forum/topic.asp?forum=228&...
    (En informatie lekker handig (imo) in één draad)

    Published: 14:00 11.10.2006 GMT+2 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562
    Crucell Announces PER.C6® Commercial Licensing Agreement with ADImmune Corporation
    Leiden, The Netherlands, October 11, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a non-exclusive PER.C6® commercial license agreement with the Taiwan-based vaccine company ADImmune Corporation.
    ADImmune intends to use the PER.C6® cell line technology to develop and commercialize a vaccine against Japanese encephalitis virus in Taiwan and China.
    Under the terms of the agreement, ADImmune will pay a license issuance fee, annual maintenance fees and royalties on future product sales. Further financial details were not disclosed.

    Tussen haakjes:(Japanese Encephalitis, 2005:
    cws.huginonline.com/C/132631/PR/20050...
    cws.huginonline.com/C/132631/PR/20051...
    www.singvax.com/
    www.singvax.com/download/SingVax-Octo... )

    Crucell announces influenza alliance with ADImmune Corporation
    Published: 08:00 22.03.2007 GMT+1 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562
    Crucell announces influenza alliance with ADImmune Corporation
    Leiden, The Netherlands, March 22, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has completed an influenza alliance with Taiwanese-based ADImmune Corporation. Under the terms of the deal, ADImmune will use Crucell's virosome technology to produce a virosomal adjuvanted influenza vaccine for specified markets: Taiwan, Japan and Macau. Additionally, ADImmune will produce influenza antigen, which Crucell may purchase for the production of its vaccine product, Inflexal® V. Crucell will obtain a 20% equity stake in ADImmune. Financial details were not disclosed.

    "With the demand for Inflexal® V presently beating current market supply, Crucell is convinced of an excellent growth potential for its influenza vaccine," said Dr. Ronald H.P. Brus, Crucell's President and Chief Executive Officer. "Inflexal® V is a distinguishable product that we intend to expand further into existing and new markets. The future additional supply of antigen from ADImmune will increase our possibilities to do this."

    ADImmune is already employing Crucell's PER.C6® technology to develop and commercialize a vaccine against Japanese encephalitis virus in Taiwan and China.

    About Virosome Technology
    Virosomal technology is a broadly applicable delivery system for antigens, DNA/RNA or therapeutic drugs. Virosomal based vaccines do not require additional adjuvants, which are known to cause adverse reactions such as irritation and inflammation at the injections site, to enhance the immune response. As a result, virosomal based vaccines have superior immunogenicity and tolerability. Inflexal® V is a virosomal adjuvanted influenza vaccine that has excellent safety and tolerability. Epaxal® is the first virosomal adjuvanted vaccine for Hepatitis A, with excellent efficacy, providing immunity for up to 20 years.

    photo.ntio.org.tw/Trade/Crucell_ADI_w...

    Bijlage:
  2. flosz 17 september 2008 12:00
    By gogogoo.
    09/17/08 14:30

    Taiwan`s first vaccine production plant to be operational in 2009

    Taipe (ANTARA News/Asia Pulse) - The ADImmune Corporation (ADI) unveiled plans Tuesday to operate Asia's first vaccine production plant in line with European standards, with an aim to provide adequate supplies of influenza vaccines and to develop new vaccines.

    Under the NT$2.8-billion (US$87.28 million) project, the plant is expected to be completed next year and it will have the capacity to produce more than 30 million doses of egg-based influenza vaccines per year, according to ADI's chairman and CEO Chi Steve Chan.

    The vaccines target markets both at home and abroad through the network of the Dutch company Crucell, Chan said, adding that his company's products will be the first from Asia to be sold on the European market.

    Source:
    Business in Asia Today - Sept. 17, 2008
    published by Asia Pulse
    COPYRIGHT © 2008
    www.antara.co.id/en/arc/2008/9/17/tai...
    udn.com/NEWS/HEALTH/HEA2/4520194.shtml
    udn.com/NEWS/FINANCE/FIN1/4513733.shtml
    www.iex.nl/forum/topic.asp?forum=228&...
    *********************

    By MeawandMoo1 op vr jun 22, 2007.
    N.a.v. vragen en antwoorden AVA:

    Op 1 juni 2007 is gedurende de presentatie aangegeven dat ADImmune ongeveer 15 miljoen dosis voor Crucell gaat leveren.

    De gestelde vragen:
    Zijn deze hoeveelheid dosissen nog steeds correct?
    Over hoeveel jaar worden deze hoeveelheid dosis geleverd?
    Wanneer verwacht Crucell de eerste geleverde dosissen vanuit ADImmune?
    Heeft ADImmune een minimale leveringsverplichting per jaar aan Crucell
    Heeft Crucell een minimale afname verplichting van ADImunne
    Heeft Crucell het recht om het belang in ADImmune verder uit te breiden?
    Heeft Crucell de verplichting om een minimale hoeveelheid aandelen in ADImmune aan te houden?
    Zo ja, hoeveel jaar is dat?

    De ontvangen antwoorden:
    Onze excuses dat we in gebreken zijn gebleven om ook uw andere vragen te beantwoorden. Ik heb deze direct kunnen voorleggen aan de Management Board en hierbij hun reactie:

    "Het aantal van 15 miljoen dosissen per jaar is juist. Dit betreft de uiteindelijke hoeveelheid per jaar, de eerste leveringen verwachten wij binnen 2 tot 3 jaar. Op de andere vragen kunnen wij helaas geen specifiek antwoord geven, deze zaken maken deel uit van de overeenkomst met AdImmune waarvan wij met elkaar hebben afgesproken dat deze niet in detail bekend gemaakt zullen worden."
    **************************

    By bilbo3
    uit het SEC jaarverslag blijken de financiële details van deze deal:
    "ADImmune Corporation
    In March 2007, we announced that we have completed an influenza alliance with Taiwanese-based ADImmune Corporation. Under the terms of the deal, ADImmune will use our virosome technology to produce a virosomal adjuvanted influenza vaccine for specified markets: Taiwan, Japan and Macau. Additionally, ADImmune will produce influenza antigen, which we may purchase for the production of our vaccine product, Inflexal V.

    In consideration of the rights and licenses granted in respect of the technology, ADImmune shall pay an amount of € 8.7 million (NT$ 394,887). We will obtain a 20% equity stake in ADImmune for which we will pay ADImmune an amount € 8.7 million (NT$ 394,887). We expect to complete these transactions during 2007."
    Bijlage:
  3. flosz 17 september 2008 12:02
    ADImmune Corporation, otherwise called “Kuo Kwang Biotechnology Company”, formerly Kuo Kwang Serum and Vaccine Laboratories, was founded in 1965 through the technical support of the Kitasato Institute, one of the biggest developers and producers of vaccines in Japan. ADImmune is the only human vaccine manufacturer in Taiwan. Under strict cGMP regulations, ADImmune produces Japanese encephalitis vaccine (JEV) and tetanus toxoid. The former item commands 100% of the local market while the later occupied 50% of the market.
    In 1997, ADImmune doubled its capital and brought in new management to meet with new financial, technical and regulatory needs. With several new candidates in the product pipeline, ADImmune is actively looking for advanced technologies in the development and production of biologics for disease prevention and treatment.
    Since 1998, ADImmune received grants from the Ministry of Economic Affairs to develop new technology and products, including the new production process of JEV, using kidney cell line from African Green Monkey as a vehicle under a serum-free cell growth condition. The clinical trials are scheduled to begin in 2008. Another major program focused by the company is the platform technology of “DNA Vaccine”. ADImmune has established a collaboration program with the Developmental Center for Biotechnology and other research institues in Taiwan, to develop plasmid DNA manufacturing processes. In one of the projects that uses JEV DNA vaccine as a working model, preliminary mice studies have been completed with promising results. ADImmune believes that Japanese encephalitis being an East Asian epidemic receives little attention from mainstream pharmaceutical companies in the West. Therefore ADImmune stands a good chance of becoming a major supplier of superior quality JEV product worldwide.
    Recently the Executive Yuan Development Fund, a major government investment program, has invested directly into ADImmune with NT$512 million (US$16 million) as a sign of support that is equal to approximately 21% of post-money stake. The money will be used to build up a state-of-the-art cGMP level manufacturing plant for vaccine production and plasmid DNA contract manufacturing business.
    The Company has a factory in central Taiwan with over 10,000 square feet of GMP facilities at present. There are over 70 employees with advanced education and experience. Dr. Sy-Dar Wang CEO, has a long credential in the vaccine business and other US companies, Dr. C.C Chang held senior R&D and management position in Lederle Labs.
    www.adimmune.com.tw/english/history.asp

    KKB/KI Flu
    JAPANESE ENCEPHAUTIS VACCINE
    TETANUS TOXOID ALLUM PREOPITATED
    TUBERCULIN PPD RT 23 SSI

    www.adimmune.com.tw/english/productio...
  4. flosz 17 september 2008 12:09
    Inflexal® V is a virosomal adjuvanted Influenza vaccine (subunit), based upon the virosome technology developed and patented by the Crucell company, Berna Biotech. It is the only adjuvanted Flu vaccine licensed for all age groups (up from 6 months). The vaccine’s antigen composition follows yearly WHO recommendations.

    Inflexal® V was originally introduced in 1997, is registered in 43 countries and has extensive market experience, with more than 26 million doses confirming its safety profile. The tolerability of Inflexal® V is excellent due to its biocompatibility and purity. Neither thiomersal nor formaldehyde is contained within the vaccine, and the manufacturing process of Inflexal® V allows residual quantities of antibiotics, detergent and hen’s egg protein to be minimal compared with other influenza vaccines.

    Influenza, commonly called the flu, is a highly contagious infection of the respiratory tract that spreads from person-to-person through infectious respiratory secretion droplets caused by coughing or sneezing. Influenza outbreaks occur almost every year and their severity varies considerably. One unique aspect of influenza, compared with other viruses, is its ability to perpetually change over time, usually by mutation. This characteristic enables the virus to evade the immune system of its host, making people susceptible to the flu throughout their entire life. When infected with the virus, a person develops antibodies that work against that virus. Once the virus changes, however, the previous antibodies are unable to recognize it, necessitating an entirely new antibody response to fight off the virus. These modifications make it necessary for individuals to receive a different influenza vaccination each year, compared with one vaccination that would grant lifetime immunity.
    Each year approximately 10-20% of the world's population contracts influenza and on average 3 to 5 million people suffer severe illness. An estimated 250,000 to 500,000 people die annually from influenza-associated complications. Influenza becomes a life-threatening disease among a number of patient populations such as the very young and the elderly, and all individuals with an underlying disease. Influenza outbreaks and epidemics (November to March represents the peak season in the Northern Hemisphere) cause an increase in hospital admissions and deaths. Yearly routine immunization is therefore recommended for these risk groups by public health authorities. Occasionally a major genetic variation in the influenza virus may result in a deadly new virus strain to which the human population does not have immunity, and a global pandemic outbreak occurs. The Spanish influenza pandemic, the most severe outbreak of influenza to date, occurred from 1918 to 1920 and caused deaths worldwide ranging in estimation from 20 to 60 million.

    While the flu affects individuals of all ages, approximately 90% of flu-related deaths occur among individuals above the age of 65. People with chronic medical conditions and young children also have a higher risk of suffering influenza complications.

    The influenza virus occurs worldwide. In temperate regions, influenza occurs during the winter months, affecting the northern hemisphere from November to March and the southern hemisphere from April to September. In tropical regions influenza may occur at any time of the year.
    Influenza transmission occurs mostly by breathing in respiratory droplets that enter the air when an infected person coughs or sneezes. Transmission also occurs through direct contact with respiratory droplets or secretions, followed by touching the nose or mouth.
    Influenza leads to a variety of symptoms, ranging from mild to severe. One to four days after exposure to the virus, the illness starts very suddenly over a period of hours. Common symptoms include fever, headache, muscle ache, extreme fatigue, sore throat, cough and nasal congestion. While symptoms usually abate within one to two weeks, the virus can often lead to further, life-threatening complications, such as pneumonia. One of the most common misconceptions about influenza is that the symptoms of stomach flu (vomiting, diarrhea, and nausea) are related to influenza. Stomach flu is usually caused by bacteria or parasites and is rarely related to the influenza virus.
    The most effective way to counter influenza is to be vaccinated against influenza. Vaccination has shown to be successful in protecting against dangerous influenza-related complications that could lead to hospitalization and death. The overall effectiveness of the yearly vaccine is dependent on its ability to match the strains that cause the illness. According to the National Foundation for Infectious Diseases, the influenza vaccine can prevent disease symptoms in 70-90% of healthy young adults. Influenza vaccine manufacturers include particular strains of the virus for inclusion in the vaccine, based on annual recommendations received from the World Health Organization (WHO).

    Current influenza virus vaccines are administered via injection and are based on inactivated (killed) whole viruses that are grown in chicken eggs, harvested, chemically inactivated, purified and processed into vaccines. Throughout the multi-stage manufacturing process, the vaccine is tested for consistency, safety, and its ability to stimulate antibody production.

    Demand for influenza vaccines is expected to more than double by 2010, driven by risks of a new influenza pandemic, the world's ageing population, and broader government vaccination recommendations. The U.S. Centers for Disease Control (CDC) recently lowered the recommended age for vaccination from 65 to 50 and has added infants between the ages of six and 23 months. Across Asia, governments have already broadened their vaccination recommendations to minimize confusion between influenza and SARS infections, with Singapore now recommending annual influenza vaccination for the entire population. In Europe, recommendations could also evolve in future years. For example, since the beginning of 2003, influenza vaccination has been encouraged in Belgium for those 50 years of age and older.
    Bijlage:
  5. flosz 17 september 2008 12:14
    Crucell’s patented Virosome Technology.

    One of the challenges in vaccine development is the creation of products that contain defined antigens of high purity and efficiently induce a protective immune response. Many antigen preparations are therefore supplemented with adjuvants to enhance the body’s immune response to the specific antigens. The most commonly used and approved adjuvants for human use are aluminium salt derivatives, which are known to cause adverse reactions such as irritation and inflammation at the injection site.

    Crucell’s patented virosome technology represents a new frontier in vaccinology, simultaneously improving the delivery of specific antigens to target immune cells, while bypassing the problems of conventional adjuvant-based vaccines.

    Based on liposomes, virosomes are tiny spherical vesicles made up of a mixture of synthetic and natural phospholipids holding the influenza virus surface proteins haemagglutinin (HA) and neuraminidase (NA). The HA and NA proteins provide the virosomes with properties that enable them to fuse with cells of the immune system. By embedding proteins of other human pathogens in the vesicles, virosomes can deliver their content - the vaccine specific antigens - directly to their targets, thereby stimulating the immune system.

    Crucell’s patented virosome technology is a broadly applicable delivery system with prospective applications in areas beyond antigen-based vaccines, such as for the delivery of DNA/RNA or therapeutic drugs. Crucell has developed several methods which allow the absorption, the chemical binding and the incorporation of antigens onto/into virosomes. Therefore, virosomes offer a flexible new tool for developing novel prophylactic and even therapeutic vaccines for a variety of diseases. The virosome technology has been licensed for a number of indications on an exclusive basis to Pevion Biotech, a joint venture company with Bachem, and is still available for licensing for a number of infectious disease areas.
    Crucell is the leading company in the development and production of virosomal vaccines. Virosomes are a market approved carrier system for the delivery of pharmaceutically or immunologically active substances.

    The technology has been used to develop Crucell’s product Inflexal® V, a trivalent seasonal influenza vaccine, as well as Epaxal®, a hepatis A vaccine.
    Bijlage:
  6. [verwijderd] 17 september 2008 13:14
    IR had said a number of years ago, that they wanted to get up to 30 million doses of Flu Vacine a year. This should double the amount of Flu vaccine they are able to sell.

    Interesting that they are anticipating selling this into the European market.

    I assume they are going to be making Inflexal, but the article doesn't not specifically state that.

    15 million extra doses, starting next year. That should help the top line. Then starting in 2010, hopefully, Sanofi based Flu, worldwide, and Crucell selling it into Japan.

    But the stock continues to plummet.
  9. [verwijderd] 17 september 2008 15:02
    quote:

    aossa schreef:

    The cook AdImmune is cooking:

    JAPANESE ENCEPHALITIS VACCINE
    TETANUS TOXOID ALLUM PREOPITATED
    TUBERCULIN PPD RT 23 SSI

    and virosomal INFLEXAL (I guess)

    Stock down another 2% today. Again, something stinks. Keep trotting out the "good news" and happy feelings while the stock collapses again.
  10. [verwijderd] 17 september 2008 16:50
    Hetzelfde bericht wat uitgebreider en let op ! extra investeringen door bestaande partners!

    Taiwan's first vaccine production plant to be operational in 2009 08/09/16 19:44:46


    Vaccine plant project celebrated
    Taipei, Sep. 16 (CNA) The ADImmune Corporation (ADI) unveiled plans Tuesday to operate Asia's first vaccine production plant in line with European standards, with an aim to provide adequate supplies of influenza vaccines and to develop new vaccines.

    Under the NT$2.8-billion project, the plant is expected to be completed next year and it will have the capacity to produce more than 30 million doses of egg-based influenza vaccines per year, according to Chi Steve Chan, ADI's chairman and CEO.

    Apart from NT$500 million that has already been invested in the project, funding for the NT$2.8 billion undertaking will come from syndicated loans of NT$1 billion from eight banks that signed a contract with ADI Tuesday, and from increased investment by existing partners and stocks issued, to the tune of NT$1.3 billion.

    Chan said development of new vaccines, such as those against enterovirus 71 and the diphtheria-tetanus-a cellular pertussis (DTaP) vaccine, will be a part of the project.

    President Ma Ying-jeou expressed support for the ASI's efforts, indicating that the corporation was helping to launch a new industry.

    "Thanks to the ADI's long-term efforts and support from different sectors, biotechnology, as a new and developing industry, has the potential to achieve a breakthrough (in Taiwan), " said Ma at a press conference.

    The vaccines target markets both at home and abroad through the network of the Dutch company Crucell, Chan said at the press conference, adding that his company's products will be the first from Asia to be sold on the European market.

    Pointing to the fact that the current supply of vaccines cannot meet global demand, Chan said he is optimistic about the future of the biotech industry, adding that in the first year of the plant's operation, the revenue from its European operation is expected to reach NT$1 billion.

    In March 2007, the ADI signed an agreement with the Dutch biotech company Crucell for technology transfer. Under the agreement, influenza vaccines manufactured by the ADI will be sold in 43 countries.

    Besides, with the technology transfer, the ADI can enhance its vaccine production standards, paving the way for the production of avian influenza vaccines, said the ADI.

    Once the plant is finished, the ADI will be capable of producing 23 million doses of H5N1 avian influenza vaccines in six months in order to satisfy domestic demand, if there is outbreak of the the deadly virus, said Chan.

    The ADI, founded in 1965, is the only human vaccine manufacturer in Taiwan. (By Emmanuelle Tzeng) ENDITEM/pc 

    www.cna.com.tw/cnaeng/EnglishTopNews/...




  11. forum rang 4 aossa 17 september 2008 17:05
    Published on Taipei Times
    www.taipeitimes.com/News/taiwan/archi...

    ADImmune wins NT$1bn loan

    BIRD FLU TARGETED: The biomedical company will use the money to build a manufacturing plant to produce vaccines for a variety of contagious diseases
    By Shelley Huang
    STAFF REPORTER
    Wednesday, Sep 17, 2008, Page 2
    ADImmune Corp obtained a loan of NT$1 billion (about US$30 million) from eight banks in Taiwan yesterday to build a vaccine manufacturing plant capable of mass-producing enough avian influenza vaccines for everyone in Taiwan.

    President Ma Ying-jeou (馬英九) and Vice President Vincent Siew (蕭萬長) attended a press conference to announce the loan yesterday to show the government’s support for building “the TSMC of the biomedical field.”

    “This is an important milestone in the development of Taiwan’s biomedical industry,” Ma said, adding that Taiwan needs to “get ahead of the race.”

    He said his support for Steve Chan (詹啟賢), chairman and chief executive officer of ADImmune, was based on friendship as well as because Chan served as deputy executive director of Ma’s presidential campaign.

    ADImmune obtained the NT$1 billion loan and will complete increasing its capital to NT$1.3 billion in the near future to finance its operations.

    Combined with the NT$500 million in government investment it recently received from the Executive Yuan Development Fund, its capital injection totals NT$2.8 billion, the largest capital increase received by a Taiwanese biomedical company.

    The company plans to build a manufacturing plant that will meet the standards of both the EU and US Food and Drug Administration.

    ADImmune already has a Good Manufacturing Process (GMP) level manufacturing plant in central Taiwan.

    Once the new plant is completed, it will be able to produce 30 million shots of avian influenza vaccine a year.

    “Our first priority is the H5N1 [avian influenza] vaccine, and we have already started researching and developing new production processes for the Japanese encephalitis vaccine,” said Ho Mei-shang (何美鄉), chief managing director of ADImmune.

    “A vaccine for enterovirus is on our list as well,” Ho said.

    While the size of the company’s vaccine market was still difficult to determine, Chan said, “the demand will most certainly exceed supply.”
  12. gogogoo 22 september 2008 07:18
    Taiwan puts vaccine project on hold Fonts Size:

    E-Mail This

    Printer-Friendly





    Central News Agency
    2008-09-20 08:34 PM

    A build-own-operate (BOO) project to manufacture influenza vaccine has been called off after years of delays, delivering a setback to the country's ambitious plan to be the first developing country to build an independent and self-sufficient vaccine manufacturing capacity, government and pharmaceutical industry sources said last week.
    The project, which was launched in 2004, will be put on hold, as an operation plan submitted by Dutch pharmaceutical company Akzo Nobel was rejected by the Department of Health (DOH) earlier this month for failing to meet criteria stipulated in the Act for Promotion of Private Participation in Infrastructure Projects, a senior DOH official said on condition of anonymity.

    Although Akzo Nobel is making a final pitch by appealing the decision, a source close to the project said that "it is fair to saythe project is terminated, at least for now." Despite the frustrating experience and outcome, the government and private sectors are still enthusiastic about the vaccine BOO deals, an official of the Centers for Disease Control under the DOH said, the government has not given up hope and strongly believes that "in its second try, the project will go smoothly."

    Chi Steve Chan, chairman and CEO of ADImmune Corporation (ADI) and a prominent figure in medical and political circles, also expressed great interest in participating in the project in the future, should the government decide to re-launch it.

    The dual-purpose project, set up amid concerns over an influenza pandemic triggered by a flu virus like H5N1, was aimed at building the country's capacity to develop and manufacture influenza vaccine by using the advanced cell-based method with the cooperation of the pharmaceutical company.

    The vaccine plant under the BOO would provide seasonal influenza vaccines, for which Taiwan at present relies totally on imports, but should a pandemic occur, the facility would expand to manufacture specific vaccine to tackle the pandemic.

    Under the original design, the construction of the plant should have been completed in 2007 and should have become operational in 2008, making Taiwan the first developing country capable of manufacturing influenza vaccine.

    The facility would have produced 2.5 million doses of seasonal influenza vaccine annually, with the DOH allocating NT$4 billion for guaranteed purchases.

    But the project has been mired in difficulties arising from competition between foreign and local companies, international business mergers and complex legal issues.

    The project was at least two to three years behind schedule. Public health officials, however, have managed to find consolation in "the good news" that an influenza pandemic has not occurred.

    They have also indicated that in the past few years, local pharmaceutical companies have acquired advanced biotechnology and manufacturing abilities, pointing to cooperation between the ADI and Dutch biomedical company Crucell.

    The private venture is expected to manufacture about 30 million doses of flu vaccine per year for both the domestic and international markets, according to the ADI.


    www.etaiwannews.com/etn/news_content....
  18. flosz 22 september 2008 09:19
    quote:

    gogogoo schreef:

    A build-own-operate (BOO) project to manufacture influenza vaccine has been called off after years of delays, delivering a setback to the country's ambitious plan to be the first developing country to build an independent and self-sufficient vaccine manufacturing capacity, government and pharmaceutical industry sources said last week.
    The project, which was launched in 2004, will be put on hold, as an operation plan submitted by Dutch pharmaceutical company Akzo Nobel was rejected by the Department of Health (DOH) earlier this month for failing to meet criteria stipulated in the Act for Promotion of Private Participation in Infrastructure Projects, a senior DOH official said on condition of anonymity.

    The facility would have produced 2.5 million doses of seasonal influenza vaccine annually, with the DOH allocating NT$4 billion for guaranteed purchases.

    They have also indicated that in the past few years, local pharmaceutical companies have acquired advanced biotechnology and manufacturing abilities, pointing to cooperation between the ADI and Dutch biomedical company Crucell.

    The private venture is expected to manufacture about 30 million doses of flu vaccine per year for both the domestic and international markets, according to the ADI.

    Mooi gogogoo, duidelijke vertaling van de Boo-link op pagina 1.
    udn.com/NEWS/FINANCE/FIN1/4513733.shtml
    Gaat o.a. niet door omdat de technologie van Crucell beter is……en ipv akzo &zo 2008 is het nu ADImmune & Crucell in 2009.
    Taiwan`s first vaccine production plant to be operational in 2009
    Bijlage:
  20. wilb52 22 september 2008 09:43
    The nurses ( 5 in a row ) have just concluded the same, because I am not allowed to hold the paper myself , for I am too dangerous to the PPS of Crucell, so they told me.
    With all those 25 different names to post , it is difficult , not making mistakes, and that's why they protect me against myself.
    What a lovely nursery.

    Happy to be here again, after a weekend abroad

    (:->D)
69 Posts
Pagina: 1 2 3 4 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 910,59 +0,71%
EUR/USD 1,0771 -0,10%
FTSE 100 8.433,76 +0,63%
Germany40^ 18.773,50 +0,47%
Gold spot 2.360,72 0,00%
NY-Nasdaq Composite 16.340,87 -0,03%

Stijgers

UCB
+3,58%
Ontex
+2,78%
Lotus ...
+1,75%
Ageas
+1,69%
bpost
+1,61%

Dalers

Bekaert
-2,79%
Solvay
-2,15%
Xior
-2,03%
Deceun...
-1,96%
VGP
-1,65%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!